POTENTIATION OF 3,4-METHYLENEDIOXYMETHAMPHETAMINE-INDUCED 5-HT RELEASE IN THE RAT SUBSTANTIA NIGRA BY CLORGYLINE, A MONOAMINE OXIDASE A INHIBITOR
- 1 October 2007
- journal article
- Published by Wiley in Clinical and Experimental Pharmacology and Physiology
- Vol. 34 (10) , 1051-1057
- https://doi.org/10.1111/j.1440-1681.2007.04734.x
Abstract
The definitive version is available at www.blackwell-synergy.com1. It is well established that the commonly used recreational drugs 3,4-methylenedioxymethamphetamine (MDMA, ‘ecstasy’) and para-methoxyamphetamine (PMA) facilitate the release and prevent the reuptake of 5-hydroxytryptamine (5-HT, serotonin). Although these drugs have similar potencies for their abilities to increase the release and inhibit the re-uptake of 5-HT, PMA has greater potency as an inhibitor of monoamine oxidase (MAO)-A. 2. The present study compared the abilities of PMA and MDMA to increase extracellular 5-HT concentrations in animals with functional MAO-A and when MAO-A activity was inhibited by clorgyline. 3. Samples of extracellular fluid from rat substantia nigra were collected using microdialysis and then analysed for 5-HT and 5-hydroxyindol acetic acid (5-HIAA) by high-performance liquid chromatography coupled with electrochemical detection. The 5-HT-mediated effects on body temperature and behaviour were also recorded. Rats were pretreated with saline or 10 mg/kg, i.p., clorgyline and, 24 h later, injected with 10 mg/kg MDMA, PMA or saline. 4. Both MDMA and PMA produced significant increases in extracellular 5-HT concentrations (482 ± 83 and 726 ± 287%, respectively; P < 0.05). Rats treated with PMA and MDMA displayed significantly increased 5-HT-related behavours (P < 0.05). Furthermore, only MDMA was capable of producing additional significant increases in 5-HT concentrations (1033 ± 131%; P < 0.01) when coadministered with clorgyline. 5. The results of the present study suggest that PMA and MDMA are similar in their abilities to increase extracellular 5-HT levels in animals with functional MAO-A activity. However, coadministration of these substituted amphetamines with an MAO-A inhibitor causes significant potentiation in the ability to increase extracellular levels of 5-HT for MDMA, but not PMAKeywords
This publication has 32 references indexed in Scilit:
- 3,4-Methylenedioxymethamphetamine (MDMA) neurotoxicity in rats: a reappraisal of past and present findingsPsychopharmacology, 2006
- Plasma Drug Concentrations and Physiological Measures in ‘Dance Party’ ParticipantsNeuropsychopharmacology, 2005
- Thermoregulatory effects of 3,4-methylenedioxymethamphetamine (MDMA) in humansPsychopharmacology, 2005
- Effects of 3,4-methylenedioxymethamphetamine (MDMA, ‘Ecstasy’) and para-methoxyamphetamine on striatal 5-HT when co-administered with moclobemideBrain Research, 2005
- The Pharmacology and Clinical Pharmacology of 3,4-Methylenedioxymethamphetamine (MDMA, “Ecstasy”)Pharmacological Reviews, 2003
- Dancing with “Death”: P-Methoxyamphetamine Overdose and Its Acute ManagementJournal of Toxicology: Clinical Toxicology, 2003
- The health effects of ecstasy: a literature reviewDrug and Alcohol Review, 2002
- Pharmacology of MDMA in HumansAnnals of the New York Academy of Sciences, 2000
- MDMA (Ecstasy) Inhibition of MAO Type A and Type B: Comparisons with Fenfluramine and Fluoxetine (Prozac)Neuropsychopharmacology, 1994
- STUDIES IN VIVO ON THE RELATIONSHIP BETWEEN BRAIN TRYPTOPHAN, BRAIN 5‐HT SYNTHESIS AND HYPERACTIVITY IN RATS TREATED WITH A MONOAMINE OXIDASE INHIBITOR AND L‐TRYPTOPHANJournal of Neurochemistry, 1971